{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:19Z","timestamp":1793320639996,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":120,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69708-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:05:04Z","timestamp":1774458304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI\/SNF alterations: a phase II basket study"],"prefix":"10.1038","volume":"17","author":[{"given":"Mrinal","family":"Gounder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-3844","authenticated-orcid":false,"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-4809","authenticated-orcid":false,"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-3519","authenticated-orcid":false,"given":"Mark","family":"Agulnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-4029","authenticated-orcid":false,"given":"Tom Wei-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-7922","authenticated-orcid":false,"given":"Ravin","family":"Ratan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Dileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-9061","authenticated-orcid":false,"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel G.","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Szanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7122-8186","authenticated-orcid":false,"given":"Neal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-8060","authenticated-orcid":false,"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"69708_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/978-1-4939-1804-1_23","volume":"1238","author":"Y Wu","year":"2015","unstructured":"Wu, Y., Sarkissyan, M. & Vadgama, J. V. Epigenetics in breast and prostate cancer. Methods Mol. Biol. 1238, 425\u2013466 (2015).","journal-title":"Methods Mol. Biol."},{"key":"69708_CR2","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1073\/pnas.95.12.6870","volume":"95","author":"JG Herman","year":"1998","unstructured":"Herman, J. G. et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95, 6870\u20136875 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69708_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564\u2013569 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"69708_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng, Y. et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 4, 62 (2019).","journal-title":"Signal Transduct. Target. Ther."},{"key":"69708_CR5","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"ML Eich","year":"2020","unstructured":"Eich, M. L., Athar, M., Ferguson, J. E. 3rd & Varambally, S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res. 80, 5449\u20135458 (2020).","journal-title":"Cancer Res."},{"key":"69708_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","volume":"14","author":"A Laugesen","year":"2014","unstructured":"Laugesen, A. & Helin, K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14, 735\u2013751 (2014).","journal-title":"Cell Stem Cell"},{"key":"69708_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal, P. & Roberts, C. W. M. The SWI\/SNF complex in cancer - biology, biomarkers and therapy. Nat. Rev. Clin. Oncol. 17, 435\u2013448 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69708_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4161\/cbt.8.5.8019","volume":"8","author":"CW Roberts","year":"2009","unstructured":"Roberts, C. W. & Biegel, J. A. The role of SMARCB1\/INI1 in development of rhabdoid tumor. Cancer Biol. Ther. 8, 412\u2013416 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"69708_CR9","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","volume":"20","author":"K Mardinian","year":"2021","unstructured":"Mardinian, K., Adashek, J. J., Botta, G. P., Kato, S. & Kurzrock, R. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol. Cancer Ther. 20, 2341\u20132351 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"69708_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","volume":"18","author":"BG Wilson","year":"2010","unstructured":"Wilson, B. G. et al. Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation. Cancer cell 18, 316\u2013328 (2010).","journal-title":"Cancer cell"},{"key":"69708_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13, 104 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"69708_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677\u2013692 (2013).","journal-title":"Cancer Cell"},{"key":"69708_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","volume":"37","author":"W B\u00e9guelin","year":"2020","unstructured":"B\u00e9guelin, W. et al. Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell 37, 655\u2013673.e611 (2020).","journal-title":"Cancer Cell"},{"key":"69708_CR14","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.1073\/pnas.1303800110","volume":"110","author":"SK Knutson","year":"2013","unstructured":"Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110, 7922\u20137927 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69708_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm.3968","volume":"21","author":"KH Kim","year":"2015","unstructured":"Kim, K. H. et al. SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21, 1491\u20131496 (2015).","journal-title":"Nat. Med."},{"key":"69708_CR16","doi-asserted-by":"publisher","first-page":"12249","DOI":"10.1073\/pnas.1703966114","volume":"114","author":"T Januario","year":"2017","unstructured":"Januario, T. et al. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI\/SNF mutant tumors. Proc. Natl. Acad. Sci. USA 114, 12249\u201312254 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69708_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep25239","volume":"6","author":"JK Shen","year":"2016","unstructured":"Shen, J. K. et al. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of synovial sarcoma in vitro. Sci. Rep. 6, 25239 (2016).","journal-title":"Sci. Rep."},{"key":"69708_CR18","doi-asserted-by":"publisher","first-page":"e0158888","DOI":"10.1371\/journal.pone.0158888","volume":"11","author":"S Kawano","year":"2016","unstructured":"Kawano, S. et al. Preclinical evidence of anti-tumor activity induced by EZH2 inhibition in human models of synovial sarcoma. PloS One 11, e0158888 (2016).","journal-title":"PloS One"},{"key":"69708_CR19","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41379-022-01148-x","volume":"35","author":"JK Dermawan","year":"2022","unstructured":"Dermawan, J. K. et al. The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms. Mod. Pathol. 35, 1900\u20131909 (2022).","journal-title":"Mod. Pathol."},{"key":"69708_CR20","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y. et al. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 29, 3044\u20133060 (2022).","journal-title":"Curr. Oncol."},{"key":"69708_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/ng.2928","volume":"46","author":"P Ramos","year":"2014","unstructured":"Ramos, P. et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat. Genet. 46, 427\u2013429 (2014).","journal-title":"Nat. Genet."},{"key":"69708_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cancergen.2014.10.004","volume":"207","author":"F Bourdeaut","year":"2014","unstructured":"Bourdeaut, F., Chi, S. N. & Fr\u00fchwald, M. C. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013. Cancer Genet. 207, 346\u2013351 (2014).","journal-title":"Cancer Genet."},{"key":"69708_CR23","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-19-3797","volume":"26","author":"M Tischkowitz","year":"2020","unstructured":"Tischkowitz, M. et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines. Clin. Cancer Res. 26, 3908\u20133917 (2020).","journal-title":"Clin. Cancer Res."},{"key":"69708_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/oncolo\/oyac040","volume":"27","author":"J Gantzer","year":"2022","unstructured":"Gantzer, J. et al. Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors. Oncologist 27, 501\u2013511 (2022).","journal-title":"Oncologist"},{"key":"69708_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/neuonc\/nos285","volume":"15","author":"I Alimova","year":"2013","unstructured":"Alimova, I. et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol. 15, 149\u2013160 (2013).","journal-title":"Neuro Oncol."},{"key":"69708_CR26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ng.2931","volume":"46","author":"L Witkowski","year":"2014","unstructured":"Witkowski, L. et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 46, 438\u2013443 (2014).","journal-title":"Nat. Genet."},{"key":"69708_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder, M. et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 21, 1423\u20131432 (2020).","journal-title":"Lancet Oncol."},{"key":"69708_CR28","unstructured":"Epizyme, Inc. TAZVERIK\u00ae (tazemetostat). Prescribing Information, Vol. 2024 (Epizyme, Inc., 2024)."},{"key":"69708_CR29","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1200\/JCO.2022.40.16_suppl.10040","volume":"40","author":"SN Chi","year":"2022","unstructured":"Chi, S. N. et al. Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1\u2013negative tumors. J. Clin. Oncol. 40, 10040 (2022).","journal-title":"J. Clin. Oncol."},{"key":"69708_CR30","doi-asserted-by":"crossref","unstructured":"Gounder, M. Efficacy, Safety, and Immune Priming Effect of Tazemetostat in Patients with Epithelioid Sarcoma, Vol. 38 (ASCO, 2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.11564"},{"key":"69708_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1309\/AJCPU98ABIPVJAIV","volume":"131","author":"L Chbani","year":"2009","unstructured":"Chbani, L. et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am. J. Clin. Pathol. 131, 222\u2013227 (2009).","journal-title":"Am. J. Clin. Pathol."},{"key":"69708_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fonc.2012.00114","volume":"2","author":"KF Ginn","year":"2012","unstructured":"Ginn, K. F. & Gajjar, A. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front. Oncol. 2, 114 (2012).","journal-title":"Front. Oncol."},{"key":"69708_CR33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41379-018-0002-1","volume":"31","author":"AR Shih","year":"2018","unstructured":"Shih, A. R. et al. Clinicopathologic characteristics of poorly differentiated chordoma. Mod. Pathol.: Off. J. U. S. Can. Acad. Pathol., Inc. 31, 1237\u20131245 (2018).","journal-title":"Mod. Pathol.: Off. J. U. S. Can. Acad. Pathol., Inc."},{"key":"69708_CR34","doi-asserted-by":"publisher","first-page":"100771","DOI":"10.1016\/j.currproblcancer.2021.100771","volume":"45","author":"MF Wedekind","year":"2021","unstructured":"Wedekind, M. F., Widemann, B. C. & Cote, G. Chordoma: current status, problems, and future directions. Curr. Probl. Cancer 45, 100771 (2021).","journal-title":"Curr. Probl. Cancer"},{"key":"69708_CR35","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.3390\/cancers15153806","volume":"15","author":"C Nze","year":"2023","unstructured":"Nze, C. et al. A phase II clinical trial of pembrolizumab efficacy and safety in advanced renal medullary carcinoma. Cancers 15, 3806 (2023).","journal-title":"Cancers"},{"key":"69708_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11060-019-03239-3","volume":"144","author":"RN Nachwalter","year":"2019","unstructured":"Nachwalter, R. N. et al. Treatment of dedifferentiated chordoma: a retrospective study from a large volume cancer center. J. Neurooncol. 144, 369\u2013376 (2019).","journal-title":"J. Neurooncol."},{"key":"69708_CR37","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41594-020-0466-9","volume":"27","author":"MJ McBride","year":"2020","unstructured":"McBride, M. J. et al. The nucleosome acidic patch and H2A ubiquitination underlie mSWI\/SNF recruitment in synovial sarcoma. Nat. Struct. Mol. Biol. 27, 836\u2013845 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"69708_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cell.2013.02.036","volume":"153","author":"C Kadoch","year":"2013","unstructured":"Kadoch, C. & Crabtree, G. R. Reversible disruption of mSWI\/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 153, 71\u201385 (2013).","journal-title":"Cell"},{"key":"69708_CR39","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433\u20131442 (2020).","journal-title":"Lancet Oncol."},{"key":"69708_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5483\/BMBRep.2022.55.12.174","volume":"55","author":"SH Lee","year":"2022","unstructured":"Lee, S. H. et al. The role of EZH1 and EZH2 in development and cancer. BMB Rep. 55, 595\u2013601 (2022).","journal-title":"BMB Rep."},{"key":"69708_CR41","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1158\/0008-5472.CAN-23-2924","volume":"83","author":"Y Kazansky","year":"2023","unstructured":"Kazansky, Y. & Kentsis, A. Epigenetic cooperativity as a therapeutic vulnerability in cancer. Cancer Res. 83, 3827\u20133829 (2023).","journal-title":"Cancer Res."},{"key":"69708_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"69708_CR43","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen, P. Y. et al. Response assessment in neuro-oncology clinical trials. J. Clin. Oncol. 35, 2439\u20132449 (2017).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69708-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:45:14Z","timestamp":1784817914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69708-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69708"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69708-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.G. reports Personal Honoraria\/Advisory Boards and\/or Associated Research Paid to Institution from Aadi, Ayala, Agios\/Servier, Bayer, Boehringer Ingelheim, Daiichi, Foghorn, GSK, Epizyme, Ikena, Karyopharm, Kura, Regeneron, Rain, Springworks, Tracon and TYME; Other: Guidepoint, GLG, Third Bridge; Flatiron Health CME Honoraria: Medscape, More Health, Physicians Education Resource, MJ LifeSciences and touchIME; Royalties: Wolters Kluwer; patents with MSKCC (GODDESS PRO); Grants from Food and Drug Administration (R01 FD005105) and the National Cancer Institute, National Institutes of Health (P30CA008748)\u2014core grant (CCSG shared resources and core facility). P.S. institution has received research funding support from Adcendo, Eisai, G1 Therapeutics, Merck & Co., ONA Therapeutics, PharmaMar, and Sartar Therapeutics; has served a consultancy or advisory role for Adcendo, Boehringer Ingelheim, Boxer Capital, Cogent Biosciences, Deciphera, Ellipses Pharma, Exelixis, Guidepoint Global, IDRx, LLX Solutions, Medpace, Merck Healthcare KGaA, NEC OncoImmunity AS, Oncode accelerator, SERVIER, Studiecentrum voor Kernenergie, Telix Pharmaceuticals, Thermosome, Transgene, and UCB. R.L.J has received research grants from Merck Sharp & Dohme, and personal fees from Adaptimmune, Blueprint, Clinigen, Daiichi, Deciphera, Eisai, Epizyme, Immunedesign, Lilly, Merck, PharmaMar, Tracon, and UptoDate. S.S. reports outside the scope of this manuscript advisory board roles with Bayer, Boehringer, Daiichi, Ikena, Nec Oncology, Pharma Essentia, Regeneron, Servier; invited speaker roles for Bayer, Boehringer, Gentili, PharmaMar; institutional research funding from Blueprint Medicines, Daiichi-Sankyo, Eli Lilly, Novartis, and Pfizer; and nonfinancial interests as treasurer of the Connective Tissue Oncology Society, as a secretary for the European Organisation for Research and Treatment of Cancer soft tissue and bone sarcoma group, president of the Italian Sarcoma Group, and as a scientific advisor for the Chordoma Foundation, Desmoid Foundation, Epithelioid Hemangioendothelioma Foundation, and Epithelioid Hemangioendothelioma (EHE) Rare Cancer Charity (UK). G.D.D. has received grants to Dana-Farber Cancer Institute from AbbVie, Adaptimmune, Bayer, Daiichi-Sankyo, Epizyme, GlaxoSmithKline, Ignyta, Janssen, Loxo Oncology, Novartis, Pfizer, PharmaMar, and Roche\/Genentech; personal fees from AbbVie, Adaptimmune, Bayer, Blueprint Medicines, CARIS Life Sciences, CHAMPIONS Oncology, Daiichi-Sankyo, Epizyme, EMD Serono, G1 Therapeutics, GSK, IDRx Janssen, Loxo Oncology, Mirati Therapeutics, Merrimack Pharmaceuticals, M.J. Hennessey\/OncLive, Novartis, Pfizer, PharmaMar, Roche\/Genentech Sanofi, Translate Bio, WIRB Copernicus Group, and ZioPharm; nonfinancial support from AbbVie, Daiichi-Sankyo, Epizyme, Novartis, PharmaMar, and Roche\/Genentech; other support or equity from Adaptimmune, Bayer, Bessor Pharmaceuticals, Blueprint Medicines, CARIS Life Sciences, CHAMPIONS Oncology, Daiichi-Sankyo, EMD Serono, Epizyme, ERASCA Pharmaceuticals, G1 Therapeutics, IDRx, Merrimack Pharmaceuticals, M.J. Hennessey\/OncLive, Novartis, Pfizer, Roche\/Genentech, Translate Bio, and WIRB Copernicus Group; and holds a patent on imatinib for GIST through Novartis, with royalties to Dana-Farber. G.M.C. has received personal fees from C4 Therapeutics, Epizyme, Ikena Oncology, and Daiichi-Sankyo, Inc, BioAtla, Gilead, Sonata Therapeutics, The Chordoma Foundation; nonfinancial support from Eisai, the Merck KGaA\/EMD Serono Research and Development Institute, and PharmaMar; his institution has received support for the conduct of clinical trials from Servier Pharmaceuticals, Bavarian-Nordic, Bayer, BioAtla, C4 Therapeutics, Eisai, Epizyme, Foghorn Therapeutics, Inhibrx, Ikena Oncology, Jazz Pharmaceuticals, Macrogenics, the Merck KgaA\/EMD Serono Research and Development Institute, PharmaMar, RAIN Therapeutics, Repare, Pyxis, SMP Oncology, and SpringWorks Therapeutics. M.A. has received personal fees from Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Immune Design, Janssen, and Novartis. R.C. has received grants and personal fees from Epizyme; grants from Aadi, Advenchen, Mundipharma, Novartis, Pfizer, Plexxikon, and SpringWorks Therapeutics; personal fees from Immune Design and Janssen; and nonfinancial support from GlaxoSmithKline, Janssen, and SpringWorks Therapeutics. T.J. has received grants from Aduro Pharma, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Epizyme, Polaris Pharma, and Trizell Ltd; and received nonfinancial support from Atara Pharmaceuticals. A.G. has received grants from Bayer and Boehringer Ingelheim. T.W.-W.C. has received nonfinancial support and manuscript preparation support from Epizyme; grants, personal fees, nonfinancial support, and travel expenses from Eisai; personal fees and nonfinancial support from Novartis; personal fees and travel expenses from Pfizer and Roche; and personal fees from Bayer and Eli Lilly. R.R. has received support for a sponsored study and advisory fees from Epizyme, Springworks Therapeutics, C4 Therapeutics and Inhibrx. P.D. has no conflicts to disclose. A.D. has received honoraria from and\/or served on an advisory board for 14ner, AbbVie, Amgen, AnHeart Therapeutics, ArcherDX, Ariad, AstraZeneca, Bayer, BeiGene, BergenBio, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Chugai Pharmaceutical, Elevation Oncology, EcoR1, EMD Serono, Entos, Exelixis, Genentech, Helsinn, Hengrui Therapeutics, Ignyta, Janssen, Lilly, Loxo, Merus, Millennium, Monopteros, MonteRosa, Novartis, Nuvalent, Pfizer, Prelude, Regeneron, Repare RX, Roche, Springer Healthcare, Takeda, TP Therapeutics, Treeline Bio, Tyra Biosciences, Verastem, and Zymeworks; and has consulted for 14ner\/Elevation Oncology, Applied Pharmaceutical Science, Bayer, Boundless Bio, Bristol Myers Squibb, Enlaza, Entos, Innocare, Lilly\/Loxo, MonteRosa, Nuvalent, Pfizer, Prelude, Roche\/Genentech, Treeline Bio, Two River; and received research funding paid to his institution from Foundation Medicine, GlaxoSmithKline, PharmaMar, and Taiho, Teva and was supported by the National Cancer Institute\/National Institutes of Health P30CA008748 grant; has equity in mBrace and Treeline Bio; has copyrights for Selpercatinib-Osimertinib (US 18\/041,617, pending); received royalties from Wolters Kluwer and UpToDate; received other (food\/beverage) from Boehringer Ingelheim, Merck, Merus, and Puma; and received CME honoraria from Answers in CME, Applied Pharmaceutical Science; Axis, Clinical Care Options, Doc Congress, EPG Health, Harborside Nexus, I3 Health, Imedex, Liberum, Medeni, Medscape, Med Learning, MedTalks, MJH Life Sciences, MORE Health, Ology, OncLive, Paradigm Medical Communications, Peerview Institute, PeerVoice, Physicians Education, Projects in Knowledge, Resources, Remedica Ltd, Research to Practice, RV More, Targeted Oncology, TouchIME, and WebMD. G.G.M. has served as a consultant for Bristol Myers Squibb, Ipsen, Eisai, MSD, and Pfizer. He has received a research grant from MSD-AVENIR. A.S. is an employee of and owns stock in Epizyme, Inc., an Ipsen company. N.G. is an employee of Ipsen. N.M.T. has received honoraria from Bristol Myers Squibb, Eisai Medical Research, Eli Lilly, Exelixis, Ipsen, Neoleukin Therapeutics; Novartis, Nektar, Ono Pharmaceutical, Oncorena, Pfizer, and Surface Oncology; served as a consultant or advisor for Bristol Myers Squibb, Eisai Medical Research, Exelixis, Nektar, Neoleukin Therapeutics, Novartis, Oncorena, Ono Pharmaceutical, Pfizer, and Surface Oncology, Ipsen; received research funding from Arrowhead Pharmaceuticals, Bristol Myers Squibb, Calithera Bioscience, Eisai, Epizyme, Exelixis, Lilly, Mirati Therapeutics, Nektar Therapeutics, Pfizer, and Takeda; and received support for travel, accommodation, and\/or expenses from Bristol Myers Squibb, Eisai Medical Research, Ipsen, Lilly Oncology, Nektar, Neoleukin Therapeutics, Novartis, Onco Pharmaceuticals, Oncorena, Pfizer, and Surface Oncology.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7120"}}